Cisplatin (P), etoposide (E) and gemcitabine (G), in untreated patients with small cell lung cancer (SCLC): Preliminary results of a multi-institutional phase II trial

Marinis, Filippo de; Cortesi, Enrico; Paoluzzi, Luca; Cipri, A.; Portalone, Luigi; Nelli, Fabrizio; Giampaolo, M.; Ariganello, Ottavio; Diana, Francesco; Ramponi, Sara

doi:10.1016/s0169-5002(00)80215-9

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topotecan-etoposide, carboplatin-vinorelbine, cisplatin-etoposide-gemcitabine, and gemcitabine-carboplatin combinations have recently produced response rates of 54-76% with grade 4 neutropenia 25-60% in populations of median age >65 years. [129][130][131][132] Elderly patients with a good prognosis, determined by pretreatment characteristics, 133 with limited stage SCLC require treatment with the aim of attaining long term survival. In patients with poorer prognoses palliative chemotherapy should be offered, remembering the high incidence of life threatening sepsis in these patients that can be ameliorated with prophylactic G-CSF or antibiotics.…”

Section: Treatment Strategies For Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

Lung volume reduction surgery for severe emphysema increases exercise capacity but not does not affect mortality

Lawson¹

2003

Thorax

View full text Add to dashboard Cite

Section: Treatment Strategies For Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

Lung volume reduction surgery for severe emphysema increases exercise capacity but not does not affect mortality

Lawson¹

2003

Thorax

View full text Add to dashboard Cite

“…The agent has proved activity in phase II trials (table 9) but data on its activity in combination regimens is restricted. The Italian "Lazio" group [106] added gemcitabine to the EP regimen in treatment of 43 patients, limited as well as extensive stage disease. The overall response rate was 68% with CR rates of 24% in limited stage and 0% in extensive stage.…”

Section: Gemcitabinementioning

confidence: 99%

Chemotherapy in small cell lung cancer

Østerlind¹

2001

Eur Respir J

View full text Add to dashboard Cite

Chemotherapy is the backbone in the treatment of small cell lung cancer (SCLC) and radiotherapy is an important adjunct in limited stage disease. The role of chest irradiation is now documented in three meta-analysis, based on the same body of data. Trials on timing, scheduling and fractionation could have followed a more stringent development line but altogether, the highest efficacy seems to be obtained with early, concurrent twice-daily chest irradiation. Patients in complete remission should have prophylactic cranial irradiation, which reduces the risk of brain metastases and of death from SCLC.Four series of chemotherapy seem to be sufficient in limited-stage disease while six is recommended in extensive disease. The combination of etoposide plus cis- or carboplatin is appropriate in both stages and addition of other agents has no clinically important impact on the survival. Use of haematological growth factors such as granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) may enable higher doses or more frequent dosage. Three randomized trials on GM-CSF showed a negative outcome while G-CSF support may result in better survival rates, but a more cost-efficient policy must be found. High-dose chemotherapy plus haematological stem-cell support is still under investigation but disappointing long-term survival rates means there is not much optimism for this strategy.New strategies in general are requested in the treatment of extensive-stage disease and of elderly patients. Phase II trials suggest that good-risk patients with extensive disease should be treated aggressively, intermediate-risk patients more gently, and palliation must be the primary aim in the treatment of poor-risk patients. In elderly patients impressive survival rates are obtained with 3–4 series of chemotherapy and radiation delivered in 5–10 fractions.A number of new agents are active but more trials are required before each has found a place, if any, in the treatment of small cell lung cancer. To conclude, the randomized trial is still an important instrument in clinical oncology, and trials in small cell lung cancer must be large, which is why the cooperation of organizations and multicentres is urgent.

show abstract

Cisplatin (P), etoposide (E) and gemcitabine (G), in untreated patients with small cell lung cancer (SCLC): Preliminary results of a multi-institutional phase II trial

Cited by 2 publications

References 0 publications

Lung volume reduction surgery for severe emphysema increases exercise capacity but not does not affect mortality

Lung volume reduction surgery for severe emphysema increases exercise capacity but not does not affect mortality

Chemotherapy in small cell lung cancer

Contact Info

Product

Resources

About